Tuberculosis and immune thrombocytopenia

Haematologica. 2002 Aug;87(8):ELT38.
No abstract available

MeSH terms

  • Adrenal Cortex Hormones / adverse effects
  • Adrenal Cortex Hormones / therapeutic use
  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Antitubercular Agents / adverse effects
  • Asparaginase / administration & dosage
  • Asparaginase / adverse effects
  • Comorbidity
  • Daunorubicin / administration & dosage
  • Daunorubicin / adverse effects
  • HIV Infections / complications
  • Humans
  • Immunocompromised Host
  • Immunosuppressive Agents / adverse effects
  • Immunosuppressive Agents / therapeutic use
  • Incidence
  • India / epidemiology
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • Prednisone / administration & dosage
  • Prednisone / adverse effects
  • Purpura, Thrombocytopenic, Idiopathic / complications
  • Purpura, Thrombocytopenic, Idiopathic / drug therapy
  • Purpura, Thrombocytopenic, Idiopathic / epidemiology*
  • Retrospective Studies
  • Rifampin / adverse effects
  • Thrombocytopenia / chemically induced
  • Tuberculosis / complications
  • Tuberculosis / epidemiology*
  • Vincristine / administration & dosage
  • Vincristine / adverse effects

Substances

  • Adrenal Cortex Hormones
  • Antitubercular Agents
  • Immunosuppressive Agents
  • Vincristine
  • Asparaginase
  • Prednisone
  • Rifampin
  • Daunorubicin

Supplementary concepts

  • PVDA protocol